Treatment-resistant Depression study: ALTO-207
Official title ALTO-207 in Adults With Treatment-resistant Depression (TRD)
ClinicalTrials.gov ID: NCT07553637
What this study is testing
What is ALTO-207?
ALTO-207 is an investigational medicine, being studied as a potential treatment for treatment-resistant depression (trd).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether ALTO-207 reduces depressive symptoms compared with a pretend treatment in people with treatment‑resistant depression.
- Who it's for
- You may be able to join if you are an adult with depression that has not improved after other treatments.
- What's involved
- You would take ALTO-207 or a pretend pill. You will have visits to check your mood and safety.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF.
- Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe).
- Failure to respond (\<50% improvement) to at least 2-5 antidepressant treatments (including the current treatment)
- Currently taking a stable dose of at least 1 but no more than 2 oral antidepressants at baseline
You likely can't join if
- Evidence of unstable medical condition
- Concurrent use of any prohibited medications or substance use disorder
- Diagnosed bipolar disorder or a psychotic disorder or symptoms
- Significant current PTSD symptoms or history of PTSD
- Clinically significant current impulse control difficulties
- Has a history of hypersensitivity or allergic reaction to ALTO-207 or any of its components/excipients
See the full eligibility criteria
- Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF.
- Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe).
- Failure to respond (\<50% improvement) to at least 2-5 antidepressant treatments (including the current treatment)
- Currently taking a stable dose of at least 1 but no more than 2 oral antidepressants at baseline
- Evidence of unstable medical condition
- Concurrent use of any prohibited medications or substance use disorder
- Diagnosed bipolar disorder or a psychotic disorder or symptoms
- Significant current PTSD symptoms or history of PTSD
- Clinically significant current impulse control difficulties
- Has a history of hypersensitivity or allergic reaction to ALTO-207 or any of its components/excipients
- Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
The study team makes the final eligibility decision.
Where it is enrolling
- Dothan, Alabama, United States
- Phoenix, Arizona, United States
- Chino, California, United States
- Los Angeles, California, United States
- Oakland, California, United States
- Oceanside, California, United States
- Sacramento, California, United States
- San Diego, California, United States
- San Jose, California, United States
- Valley Village, California, United States
- Saint Augustine, Florida, United States
- Albany, Georgia, United States
- Marietta, Georgia, United States
- Savannah, Georgia, United States
- Snellville, Georgia, United States
- Naperville, Illinois, United States
- Indianapolis, Indiana, United States
- Pikesville, Maryland, United States
- Rockville, Maryland, United States
- Worcester, Massachusetts, United States
+ 19 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Dothan, Alabama, United States; Phoenix, Arizona, United States; Chino, California, United States; Los Angeles, California, United States; Oakland, California, United States; Oceanside, California, United States and 33 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.